Safety, Pharmacokinetics, and Pharmacodynamics of TD‐0714, a Novel Potent Neprilysin Inhibitor in Healthy Adult and Elderly Subjects
Open Access
- 7 June 2020
- journal article
- research article
- Published by Wiley in Clinical and Translational Science
- Vol. 13 (6) , 1307-1315
Abstract
TD‐0714 is an orally active, potent, and selective inhibitor of human neprilysin (hNEP) in development for the treatment of chronic heart failure. Oral administration of TD‐0714 in rats resulted in dose‐dependent and sustained increases in plasma cyclic guanosine monophosphate (cGMP) over 24 hours consistent with NEP target engagement. Randomized, double‐blind, placebo controlled, single ascending dose (SAD; 50 to 600 mg TD‐0714) and multiple ascending dose (MAD; 10 to 200 mg TD‐0714 QD for 14 days) studies were conducted in healthy volunteers. TD‐0714 was generally well tolerated and no serious adverse events (SAEs) or clinically significant effects on vital signs or electrocardiogram parameters were observed. TD‐0714 exhibited dose‐proportional pharmacokinetics with high oral bioavailability, minimal accumulation after once daily dosing and negligible renal elimination. Pharmacodynamic (PD) responses were observed at all dose levels studied as reflected by statistically significant increases in plasma cGMP concentrations. The increases in cGMP were significantly above the baseline (~50‐100%) on Day 14 for the entire 24 hr interval indicating that sustained cGMP elevations are achieved at steady state. Maximal steady‐state cGMP response was observed in plasma and urine at doses ≥50 mg. The TD‐0714 PK‐PD relationship and safety profile was similar in elderly vs. younger adult subjects. The TD‐0714 PK and PD profiles support further clinical development of TD‐0714 and suggest the potential for once‐daily administration and predictable exposure in patients with cardiorenal diseases regardless of their renal function.Keywords
This publication has 18 references indexed in Scilit:
- Pharmacodynamic and Pharmacokinetic Profiles of Sacubitril/Valsartan (LCZ696) in Patients with Heart Failure and Reduced Ejection FractionCardiovascular Therapeutics, 2016
- The Path to an Angiotensin Receptor Antagonist-Neprilysin Inhibitor in the Treatment of Heart FailureJACC, 2015
- Natriuretic peptides and cardio-renal diseaseInternational Journal of Cardiology, 2014
- Angiotensin–Neprilysin Inhibition versus Enalapril in Heart FailureNew England Journal of Medicine, 2014
- 2013 ACCF/AHA Guideline for the Management of Heart FailureJACC, 2013
- Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeuticsEuropean Heart Journal, 2012
- Single‐Dose Pharmacokinetics, Pharmacodynamics, Tolerability, and Safety of the Soluble Guanylate Cyclase Stimulator BAY 63‐2521: An Ascending‐Dose Study in Healthy Male VolunteersThe Journal of Clinical Pharmacology, 2008
- Pharmacokinetics and pharmacodynamics of the vasopeptidase inhibitor, omapatrilat in healthy subjectsBritish Journal of Clinical Pharmacology, 2003
- Comparison of Omapatrilat and Enalapril in Patients With Chronic Heart FailureCirculation, 2002
- Inhibition of endopeptidase EC 24.11 in humans. Renal and endocrine effects.Hypertension, 1990